Age, Biography and Wiki
Changjoon Justin Lee was born on 21 March, 1966 in Gimpo, South Korea, is an American neuroscientist. Discover Changjoon Justin Lee's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 57 years old?
Popular As |
N/A |
Occupation |
N/A |
Age |
57 years old |
Zodiac Sign |
Aries |
Born |
21 March, 1966 |
Birthday |
21 March |
Birthplace |
Gimpo, South Korea |
Nationality |
South Korea
|
We recommend you to check the complete list of Famous People born on 21 March.
He is a member of famous with the age 57 years old group.
Changjoon Justin Lee Height, Weight & Measurements
At 57 years old, Changjoon Justin Lee height not available right now. We will update Changjoon Justin Lee's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
Physical Status |
Height |
Not Available |
Weight |
Not Available |
Body Measurements |
Not Available |
Eye Color |
Not Available |
Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
Family |
Parents |
Not Available |
Wife |
Not Available |
Sibling |
Not Available |
Children |
Not Available |
Changjoon Justin Lee Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Changjoon Justin Lee worth at the age of 57 years old? Changjoon Justin Lee’s income source is mostly from being a successful . He is from South Korea. We have estimated Changjoon Justin Lee's net worth, money, salary, income, and assets.
Net Worth in 2024 |
$1 Million - $5 Million |
Salary in 2024 |
Under Review |
Net Worth in 2023 |
Pending |
Salary in 2023 |
Under Review |
House |
Not Available |
Cars |
Not Available |
Source of Income |
|
Changjoon Justin Lee Social Network
Timeline
Changjoon Justin Lee is an American neuroscientist specializing in the field of glioscience.
He served as the Director of Center for Neuroscience at the Korea Institute of Science and Technology and later founded the WCI Center for Functional Connectomics as part of the World Class Institute Program.
While under an Illinois State Scholarship and working as a junior research assistant in the lab of Professor Louis Seiden, Lee majored in chemistry and obtained his B.A. from the University of Chicago in 1990.
He then moved to New York where he enrolled in the Graduate School of Arts and Sciences of Columbia University where he earned his M.S. and Ph.D. in neurophysiology under the Department of Physiology and Cellular Biophysics.
His doctoral thesis adviser was Professor Amy B. MacDermott, whose lab he worked in as a research technician and later as a graduate research assistant upon recipient of his M.S.
Before the first year of his joint M.S. and Ph.D. study, he worked as a research assistant in Emily Foster's lab at Michael Reese Hospital.
Within Columbia University, he was also a research technician in Professor Martin Low's lab.
He then completed a three-year postdoc position in the lab of Professor Traynelis at Emory University in the Department of Pharmacology.
His sponsor was Dr. Stephen Traynelis and his research scope was the modulation of NMDA receptors by protease-activated receptors.
During the postdoc position, he visited the Korea Institute of Science and Technology (KIST) and was influenced by Shin Hee-sup to join KIST, which he did in 2004 as a senior research scientist.
As a part of World Class Institute program (WCI), he founded the WCI Center for Functional Connectomics in 2009 and served as the organizing deputy director of the center.
Working at KIST, he became a principle research scientist in 2010 and later a tenured research scientist in 2017.
Lee participated in establishing brain science research infrastructure at KIST, first as a founding member of the Center for Neuroscience with director Shin Hee-sup.
The Center is now a constituent of KIST's Brain Science Institute.
He also helped to establish the Neuroscience Program of the University of Science and Technology (UST).
He also participated as a founding faculty of KU-KIST School of Convergence Technology.
In 2015, he established the Center for Glia-Neuron Interaction before becoming co-director of the IBS Center for Cognition and Sociality and head of the Cognitive Glioscience Group in 2018.
He has been on the editorial boards of the journals Molecular Brain and Molecular Pain and is a chief editor of Experimental Neurobiology.
Born in a rural area of Gimpo City, Lee interacted with the natural world and raised livestock at home which inspired an interest in biology.
After completion of middle school, he left South Korea and moved to the US at age 15 and started high school at Rich Central High School, Olympia Fields, Illinois.
In response to his Alzheimer's research related to causes of memory loss, Lee received the Science Day 2017 Presidential Medal of Honor.
It is known that glutamate is released from astrocytes but the exact method of their release, i.e., the release mechanism, has been controversial.
His team went on to discover two models of glutamate release; a fast mode through TREK-1 in the K2P channel and a slow mode through the Best1 channel in hippocampal astrocytes.
They found that Best1-controlled glutamate release is related to receptor mediated synaptic plasticity in the hippocampus when PAR1 is activated.
These papers also show that the key modulator for excitation-inhibition balance in the brain is mainly dependent on the levels of glutamate and GABA.
In addition to glutamate, Best1 can also release d-serine, which can act as a co-agonist of NMDA receptors to participate in synaptic plasticity.
Some of his glioscience-related research has been with identifying and characterizing several astrocytic ion channels.
His teams learned that the astrocytic two-pore potassium channel K2P has a passive conductance with a subunit composition of a heterodimer of TWIK-1 and TREK-1.
They also put forth the proposal that the heterodimer of TWIK-1 and TREK-1 could be a potential therapeutic target for epilepsy, depression, and anxiety disorders caused by concentrations of potassium ion.
The team found that the astrocytic volume-regulated anion channel (VRAC) is Tweety-homolog (Ttyh), which is notable as VRAC was proposed to be leucine-rich repeat-containing protein 8 (LRRC8).
Lee's research also showed that the astrocytic volume change through aquaporin-4 water channel is critical for synaptic plasticity.
They demonstrated that a change in the volume can directly affect spatial memory in mice, meanwhile it affects memory and language-association learning in humans.
Reactive gliosis has often referred to as the basis for neuroinflammation, which has implicated them in Alzheimer's disease and other neurodegenerative diseases but their in vivo functions have not been fully tested due to the lack of an appropriate experimental model.
In November 2018, Lee joined the IBS Center for Cognition and Sociality as a co-director with Shin Hee-sup, who he had previously met and worked with at KIST.
The findings also resulted in a technology transfer to MegaBioWood which will be prepared for a phase I clinical trial in 2019.
Shin led the Social Neuroscience Group until his retirement in 2020 while Lee leads the Cognitive Glioscience Group which focuses on four research areas: molecular glioscience, glia-neuron interaction, glial plasticity and cognition, and gliopathy.
Lee's research group has contributed to the field of gliotransmission by creating several seminal publications on the channel-mediated gamma-Aminobutyric acid (GABA) and glutamate release from astrocytes.
They later identified the biosynthetic pathway for astrocyte GABA and found monoamine oxidase B to be the key enzyme for GABA production which raised the possibility that astrocytes can directly participate in cognitive processes via astrocytic GABA.
His team also found a connection with GABA from reactive astrocytes and impaired memory in mouse models of Alzheimer's disease, leading them to propose astrocytic GABA might be a diagnostic tool, biomarker, and therapeutic target for both neurological diseases Alzheimer's and Parkinson's.
The research is notable as it revealed that astrocytes, like neurons, play a significant role in cognitive processes.